-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in US stocks | Novo Nordisk (NVO.US) fell more than 2% due to lower outlook, stock prices plummeted, and the company is facing a shareholder class action lawsuit

Zhitongcaijing·08/05/2025 14:41:13
Listen to the news

The Zhitong Finance App learned that Novo Nordisk (NVO.US) fell more than 2% to $47.64 on Tuesday. According to the news, Novo Nordisk is facing shareholder lawsuits due to a reduction in annual revenue and operating profit growth expectations. The company used the resistance faced by the GLP-1 market as the reason for the downgrade.

On July 28 (Friday), a group of Novo Nordisk shareholders filed a proposed class action lawsuit against the Danish company in federal court in New Jersey seeking to recover losses caused by the company's suspected securities fraud between May 7 and July 28, 2025. The plaintiff alleges that Novo Nordisk made overly optimistic statements and spread false and misleading statements during this period, exaggerating its growth potential, while concealing significant material adverse facts. Ultimately, stock prices plummeted due to lower performance guidelines, causing shareholder losses.